ABSTRACT
BACKGROUND: Although using pathological diagnosis is the gold standard for lung cancer diagnosis, pathological reports take a long time. Rapid on-site assessment (ROSE) is a method to determine whether the quality of the specimens is sufficient for cytopathological diagnosis, which issues a preliminary report during the operation and takes shorter time. The aim of this study is to explore the clinical significance of rapid on-site evaluation (ROSE) in the diagnosis of lung cancer in terms of real-time and accuracy. METHODS: A total of 38 suspected lung cancer cases were enrolled from August 2019 to July 2020. Patients received ROSE and pathological examinations at the same time. The coincidence rate of the two diagnostic approaches was calculated, and statistical analysis was carried out to evaluate whether the time difference between the ROSE report and the pathological report reached statistical significance. RESULTS: A total of 38 suspected lung cancer cases were enrolled from August 2019 to July 2020. Patients received ROSE and pathological examinations at the same time. The coincidence rate of the two diagnostic approaches was calculated, and statistical analysis was carried out to evaluate whether the time difference between the ROSE report and the pathological report reached statistical significance.. CONCLUSIONS: ROSE has the advantage of rapid and accurate diagnosis for lung cancer, and has great clinical significance.
